Allison Rohner is a highly accomplished Senior Scientist at Pfizer, bringing over 20 years of extensive experience in the biotechnology and pharmaceutical industries. Her expertise lies in evaluating the pharmacological effects of therapeutics on relevant diseases, with a particular focus on oncology. In her current...
Allison Rohner is a highly accomplished Senior Scientist at Pfizer, bringing over 20 years of extensive experience in the biotechnology and pharmaceutical industries. Her expertise lies in evaluating the pharmacological effects of therapeutics on relevant diseases, with a particular focus on oncology. In her current role, Allison is at the forefront of innovative research, executing and analyzing tumor infiltrating lymphocytes (TILs) in various models, including xenograft, syngeneic, and genetically engineered mouse models (GEMM). This work is pivotal in understanding drug effects within the tumor microenvironment, leveraging advanced techniques such as multi-parameter flow cytometry.
Allison's proficiency in immune profiling of humanized mouse models has been instrumental in advancing Pfizer's drug development pipeline. She has designed and conducted over ten color flow panels using state-of-the-art instruments like LSRII, Fortessa X20, and Sony, showcasing her technical acumen and commitment to precision in experimental design. Her comprehensive skill set encompasses a wide array of methodologies, including RT-PCR, immunoassays, and aseptic techniques, all of which are critical in the realm of cell biology and drug development.
Through her dedication and innovative approach, Allison has significantly contributed to the understanding of immune responses in cancer therapy, positioning herself as a key player in the ongoing quest to develop effective treatments. Her ability to translate complex biological data into actionable insights underscores her value as a scientist and her commitment to advancing the field of oncology at Pfizer.
